Xeris Biopharma Holdings Inc. Stock
There is an upward development for Xeris Biopharma Holdings Inc. compared to yesterday, with an increase of €0.090 (1.390%).
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Xeris Biopharma Holdings Inc..
As a result the target price of 8 € shows a positive potential of 27.19% compared to the current price of 6.29 € for Xeris Biopharma Holdings Inc..
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 1.390% | -4.145% | 5.456% | 102.217% | 2.534% | 478.538% | 47.831% |
| Ardelyx Inc. | -2.020% | 11.247% | 35.898% | 39.208% | 37.337% | 133.587% | 16.350% |
| Evolus Inc | 2.910% | -3.318% | -32.562% | -67.360% | -25.138% | -56.825% | -12.559% |
| Champions Oncology Inc | 2.610% | -4.167% | 0.000% | -42.500% | -0.862% | 43.750% | -37.158% |
Comments
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat